KA Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (26 Apr 2024 @ 16:00):

Kineta, Inc., a clinical stage biotechnology company, develops immunotherapies for oncology, neuroscience, and biodefense. It serves private, government, and industry partners...

Stats
Today's Volume	130 576
Average Volume	374 782
Market Cap	6.69M
EPS	$0 ( 2024-03-29 )
Next earnings date	( $-0.260 ) 2024-05-09
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.480
ATR14	$0.00900 (1.48%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-14	Iadonato Shawn	Buy	225 000	Stock Option (Right to Buy)
2024-04-14	Philips Craig W.	Buy	225 000	Stock Option (Right to Buy)
2024-04-14	Baker Keith	Buy	225 000	Stock Option (Right to Buy)
2024-04-14	Guillaudeux Thierry	Buy	225 000	Stock Option (Right to Buy)
2023-12-06	Bartoszek Raymond J.	Buy	250	Common Stock

INSIDER POWER
92.48
Last 63 transactions
Buy: 2 025 106 \| Sell: 94 301

Volume Correlation

Long: 0.27 (neutral)

Short: 0.37 (neutral)

Signal:(60.096) Neutral

Kineta, Inc. Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Kineta, Inc. Correlation - Currency/Commodity

0.37
( neutral )

-0.39
( neutral )

0.00
( neutral )

0.44
( neutral )

0.00
( neutral )

-0.56
( weak negative )

Kineta, Inc. Financials

Annual	2023
Revenue:	$5.44M
Gross Profit:	$5.43M (99.83 %)
EPS:	$-1.280

FY	2023
Revenue:	$5.44M
Gross Profit:	$5.43M (99.83 %)
EPS:	$-1.280

FY	2022
Revenue:	$1.95M
Gross Profit:	$1.22M (62.42 %)
EPS:	$-12.80

FY	2021
Revenue:	$9.09M
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.152

Financial Reports:

No articles found.

Kineta, Inc.

Kineta, Inc., a clinical stage biotechnology company, develops immunotherapies for oncology, neuroscience, and biodefense. It serves private, government, and industry partners. The company has strategic partnerships with Pfizer, Genentech, Wellcome, and Samsung Biologics Co., Ltd. Kineta, Inc. was formerly known as Lecura, Inc. The company was incorporated in 2007 and is based in Seattle, Washington.